JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269622

Human BACE2 knockout SW480 cell line

Human BACE2 knockout SW480 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

BACE2 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 1 bp deletion Frameshift: 100%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

別名を表示する

ALP 56, ASP21, Asp 1, Aspartic-like protease 56 kDa, Aspartyl protease 1, BACE2_HUMAN, Beta Site Amyloid Beta A4 Precursor Protein Cleaving Enzyme 2, Beta-secretase 2, Beta-site APP cleaving enzyme 2, Beta-site amyloid precursor protein cleaving enzyme 2, DRAP, Down region aspartic protease, Downs Syndrome Region Aspartic Protease, Memapsin-1, Membrane-associated aspartic protease 1, Theta-secretase

1 Images
Next Generation Sequencing - Human BACE2 knockout SW480 cell line (AB269622)
  • NGS

Supplier Data

Next Generation Sequencing - Human BACE2 knockout SW480 cell line (AB269622)

Knockout achieved by CRISPR/Cas9; X = 1 bp deletion; Frameshift : 100%

Key facts

細胞タイプ

SW480

生物種

Human

組織

Colon

製品の状態

Liquid

form

ノックアウト検証方法

Next Generation Sequencing

ノックアウト変異

Knockout achieved by CRISPR/Cas9 X = 1 bp deletion Frameshift: 100%

疾病

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

製品の詳細

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

製品内容

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab269622-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab271146 Human wild-type SW480 cell line", "number":"AB269622-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab269622 Human BACE2 knockout SW480 cell line", "number":"AB269622-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab269622-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab269622 Human BACE2 knockout SW480 cell line", "number":"AB269622-CMP01", "productcode":"" } ] } } }

出荷温度及び保存条件

遺伝子名
BACE2
遺伝子編集のタイプ
Knockout
遺伝子編集の方法
CRISPR technology
ノックアウト検証方法
Next Generation Sequencing
出荷温度
Dry Ice
短期保存期間
1-2 weeks
短期保存温度
-196°C|-80°C
長期保存温度
-196°C

取り扱い方法

初回取り扱いガイドライン

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

継代培養ガイドライン
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2-3x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Slow growing. A partial media change is recommended at least twice between passages.
培養培地

Ham's F-12 + 10% FBS

凍結保存培地

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

BACE2 also known as beta-site APP-cleaving enzyme 2 is an aspartic acid protease. It has a molecular mass of roughly 70 kDa. This enzyme cleaves amyloid precursor protein (APP) at the beta-secretase site. BACE2 is mainly expressed in the brain but also found in other tissues like the pancreas. It shares similarity with BACE1 another protease involved in APP processing.
Biological function summary

BACE2 acts on substrates to regulate amyloidogenic processing of APP. It belongs to the peptidase A1 Family. Unlike its counterpart BACE1 which promotes amyloid-beta peptide production BACE2 has been suggested to reduce amyloid-beta formation by different substrate cleavage. Though not part of a stable complex BACE2 influences pathways related to protein processing.

Pathways

One should note that BACE2 is involved in the amyloidogenic pathway. This pathway processes APP and affects amyloid-beta levels important in neurological conditions. BACE2 acts with proteins like APP and might modulate the effects seen due to BACE1 activity. Despite overlapping functions BACE2 and BACE1 have distinct roles in this pathway impacting amyloid levels differently.

People look at BACE2 because of its connection to Alzheimer's disease and Down syndrome. BACE2 might act as a protective factor against Alzheimer's by limiting amyloid-beta accumulation. Down syndrome characterized by trisomy 21 involves heightened BACE2 expression which may modify neurodevelopment. In Alzheimer's research BACE1 has been the focus due to its role in disease progression but BACE2's contrasting effects offer a potential therapeutic angle.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

製品プロトコール

ターゲットの情報

See full target information BACE2

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com